A5044447624- CAR-T cell therapy research
- PARP inhibition in cancer therapy
- Immune cells in cancer
- DNA Repair Mechanisms
- Brain Metastases and Treatment
- Immunotherapy and Immune Responses
- Mesenchymal stem cell research
- Electrostatic Discharge in Electronics
- Virus-based gene therapy research
- Pancreatic function and diabetes
- RNA Interference and Gene Delivery
- Low-power high-performance VLSI design
- Cancer Immunotherapy and Biomarkers
- Cell death mechanisms and regulation
Brigham and Women's Hospital
2023-2025
Harvard University
2023-2025
Hospital Del Mar
2019-2020
Hospital del Mar Research Institute
2019-2020
Abstract Background Immune-checkpoint inhibitors have shown clinical benefit in non-small cell lung cancer (NSCLC) derived brain metastasis (BM), however, their efficacy to leptomeningeal (LLBM) remains poor. Methods A paired matched RNA expression dataset of patients with NSCLCs and BMs was analyzed idenfiy BM specific suppressive tumor microenvironment (TME) features. Next, we created immune-competent LLBM mouse models that mimic LLBM. We evaluated the intrathecal (IT) delivery allogeneic...
Abstract Purpose: Death receptor (DR)-targeted therapies offer a promising tumor cell-specific therapeutic strategy for highly malignant brain tumors, such as glioblastoma (GBM). However, whether DR-mediated cell death leads to activation of the adaptive immune system and impacts microenvironment (TIME) remains unknown. In this study we explored 1) immunomodulatory role secretable human DR4/5 ligand, necrosis factor (TNF)-related apoptosis-inducing ligand (S-TRAIL); 2) potential allogeneic...
Encapsulated cell-based therapies for solid tumors have shown promising results in pre-clinical settings. However, the inability to culture encapsulated therapeutic cells prior their transplantation has limited translation into clinical In this study, we created a wide variety of engineered (ThC) loaded micropore-forming gelatin methacryloyl (GelMA) hydrogel (CellDex) capsules that can be cultured vitro surgically debulked tumors. We show both allogeneic and autologous cells, such as stem...
Abstract Leptomeningeal metastasis (LM) is one of the severe disease conditions in brain (BM) and results poor prognosis reduction quality life. Immunotherapies such as anti-Programmed cell Death (PD)-1 antibodies have shown improved overall survival against non-small lung cancer (NSCLC).. However, clinical benefit patients with NSCLC derived LM still limited due to penetration therapeutic agents into cerebrospinal fluid (CSF) lack understanding tumor microenvironment LM. In this study, we...